Get the Stockscreener App
15.71
0.25%
-0.04
After Hours:
15.71
Zenas Biopharma Inc stock is traded at $15.71, with a volume of 75,657.
It is down -0.25% in the last 24 hours and up +62.13% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$15.75
Open:
$15.61
24h Volume:
75,657
Relative Volume:
0.44
Market Cap:
$657.21M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.74%
1M Performance:
+62.13%
6M Performance:
+95.89%
1Y Performance:
+0.00%
1-Day Range:
$15.30
$16.10
1-Week Range:
$15.07
$16.73
52-Week Range:
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
15.71 | 658.89M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
What are the technical indicators suggesting about Zenas BioPharma Inc.Daily Trading Guidance With Low Risk - jammulinksnews.com
Is it the right time to buy Zenas BioPharma Inc. stockMarket Forecast Data Feed For Fast Growth - jammulinksnews.com
Why is Zenas BioPharma Inc. stock attracting strong analyst attentionDaily Trading Guidance With Proven Results - jammulinksnews.com
What makes Zenas BioPharma Inc. stock price move sharplyConsistent Gain Investment Strategies Emerge - metal.it
Zenas BioPharma Inc. Shows Support at Fibonacci LevelExit Ready Momentum Stock Watchlist Expanded - metal.it
What does ZBIO's flat EPS in 2024 suggest for short-term traders? - AInvest
Zenas BioPharma Inc. Breaks Losing Streak — Is the Trend ReversingTrade Setups With AI Powered Filters Published - metal.it
Can Traders Expect Breakout From Zenas BioPharma Inc. This WeekTriple Digit Return Stock Predictions Released - metal.it
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference - The Globe and Mail
Does Zenas BioPharma Inc. stock perform well during market downturnsMarket Forecast Report For Fast Growth - jammulinksnews.com
Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS (NASDAQ:ZBIO) - Seeking Alpha
When is Zenas BioPharma Inc. stock expected to show significant growthInvest confidently with professional market insights - jammulinksnews.com
Warm Autoimmune Hemolytic Anemia Market Expands Amid Increased - openPR.com
What are the latest earnings results for Zenas BioPharma Inc.Build a strong portfolio for growth and safety - jammulinksnews.com
How does Zenas BioPharma Inc. generate profit in a changing economySuperior portfolio returns - jammulinksnews.com
How many analysts rate Zenas BioPharma Inc. as a “Buy”Invest in stocks with long-term growth potential - jammulinksnews.com
Key External Factors That Drive Zenas BioPharma Inc. Stock Price MovementsRisk Limited High Gain Trades - metal.it
Zenas BioPharma Inc. Company’s Quarterly Earnings Growth: What the Numbers SayInstant Stock Updates - metal.it
Competitive Positioning of Zenas BioPharma Inc.: Is It Leading or LaggingFree Stock Selection - metal.it
How volatile is Zenas BioPharma Inc. stock compared to the marketRecord-setting profit potential - jammulinksnews.com
Is Zenas BioPharma Inc. a Top Dividend Stock to Watch in 2025Free Investing Community - Newser
Is Zenas BioPharma Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Stock Market Forums - Newser
Is Zenas BioPharma Inc. stock overvalued or undervaluedAchieve rapid financial growth with expert picks - jammulinksnews.com
What analysts say about Zenas BioPharma Inc. stockOutstanding risk-reward balance - PrintWeekIndia
What drives Zenas BioPharma Inc. stock priceConsistent high-yield stocks - PrintWeekIndia
Is Zenas BioPharma Inc. a good long term investmentFree Real-Time Stock Data - PrintWeekIndia
Zenas BioPharma Inc. Stock Analysis and ForecastOutstanding trading profits - jammulinksnews.com
IgG4-Related Disease Market Outlook Driven by Advancing - openPR.com
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):